Table 3.
Duration of Time in Days Between Fiebig Stage (t) and Subsequent Stage (t+1) Among All Study Visits
| Stage at time t | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Stage at time +1 | I | I/II | II | III | IV | V | V/VI | N | |
| I | |||||||||
| Midpoint: median (IQR) | I/II | 3 (2–7) | |||||||
| Actual: median (IQR) | 6 (4–10) | ||||||||
| N | 3 | 3 | |||||||
| Midpoint: median (IQR) | II | 3 | 3 (2–5) | ||||||
| Actual: median (IQR) | 6 | 6 (2–8) | |||||||
| N | 1 | 11 | 12 | ||||||
| Midpoint: median (IQR) | III | — | 4 (3–6) | 3.5 (3–4) | |||||
| Actual: median (IQR) | — | 7 (5–8) | 6 (5–7) | ||||||
| N | 0 | 5 | 2 | 7 | |||||
| Midpoint: median (IQR) | IV | 18.5 (5–32) | 7 (4–8) | 6.5 (5–10.5) | 4 (1–12) | ||||
| Actual: median (IQR) | 24 (9–39) | 13 (7–16) | 12 (8.5–16.5) | 7 (2–18) | |||||
| N | 2 | 22 | 8 | 3 | 35 | ||||
| Midpoint: median (IQR) | V | 12 (7.5–13.5) | 9 (7–11) | 7 (6–11) | 10.5 (7–13) | 8 (5–12) | |||
| Actual: median (IQR) | 17 (10.5–20) | 17 (13–21) | 11 (6–21) | 14.5 (12–23.5) | 10 (7–17) | ||||
| N | 4 | 61 | 11 | 12 | 69 | 157 | |||
| Midpoint: median (IQR) | V/VI | — | — | 10.5 (10–18.5) | — | 7 (4–21) | — | ||
| Actual: median (IQR) | — | — | 20.5 (19–36) | 13 (7–41) | — | ||||
| N | 0 | 0 | 4 | 0 | 13 | 0 | 17 | ||
| Midpoint: median (IQR) | VI | — | 11 (7–13.5) | — | 12 (9–15) | 12 (8–17) | 35 (21–79) | 14 (8–24) | |
| Actual: median (IQR) | — | 22 (13.5–27) | — | 20 (18–22) | 21 (12–31) | 40 (25–103) | 24 (16–41) | ||
| N | 0 | 8 | 0 | 2 | 15 | 122 | 119 | 266 | |
| N | Total | 10 | 107 | 25 | 17 | 97 | 122 | 119 | 497 |
Days between earlier stage (t) and subsequent stage (t + 1) transitions, among 360 UWPIC subjects.